Patient Engagement Solutions LLC

Sucampo Pharmaceuticals, now a part of Mallinckrodt, is dedicated to the commercialization of innovative therapeutic solutions, including AMITIZA (lubiprostone) for pediatric functional constipation and Rescula (unoprostone isopropyl) in Japan. With a commitment to advancing development therapies, the company focuses on addressing rare diseases such as Niemann-Pick Type C and Familial Adenomatous Polyposis through its pipeline products. Having over 150 years of experience, Sucampo emphasizes quality, integrity, and community outreach as part of its corporate culture. The merger with Mallinckrodt enhances its capabilities in delivering critical medical advancements to patients in need. Generated from the website

United BioSource (UBC) is a leading provider of innovative solutions focusing on specialty therapies, combining expertise in evidence generation, patient access, and safety risk management. With a commitment to improving patient outcomes, UBC leverages real-world data and advanced technologies to navigate the complexities of drug approval and delivery. Specializing in tailored drug safety and risk management strategies, UBC stands out for its ability to deliver compliant and patient-centric support across the drug development lifecycle. The company's insights-driven approach aims to address barriers to patient access while enhancing affordability and adherence solutions for patients in need of specialty therapies. Generated from the website